Glutaryl-CoA Dehydrogenase Deficiency: Region-Specific Analysis of Organic Acids and Acylcarnitines in post mortem Brain Predicts Vulnerability of the Putamen

Abstract

The neurometabolic disorder glutaryl-CoA dehydrogenase (GCDH) deficiency is biochemically characterised by an accumulation of the marker metabolites 3-hydroxyglutaric acid, glutaric acid, and glutarylcarnitine. If untreated, the disease is complicated by acute encephalopathic crises, resulting in neurodegeneration of vulnerable brain regions, in particular the putamen. 3-Hydroxyglutaric acid is considered the major neurotoxin in this disease. There are only preliminary data concerning glutaric acid concentrations in the brains of affected children and the distribution of 3-hydroxyglutaric acid and glutarylcarnitine has not been described. In the present study, we investigated post mortem the distribution of 3-hydroxyglutaric and glutaric acids as well as glutarylcarnitine in 14 different brain regions, internal organs, and body fluids (urine, plasma, cerebrospinal fluid) in a 14-year-old boy. 3-Hydroxyglutaric acid showed the highest concentration (62 nmol/g protein) in the putamen among all brain areas investigated. The glutarylcarnitine concentration was also highest in the putamen (7.1 nmol/g protein). We suggest that the regional-specific differences in the relative concentrations of 3-hydroxyglutaric acid contribute to the pattern of neuronal damage in this disease. These results provide an explanatory basis for the high vulnerability of the putamen in this disease, adding to the strong corticostriatal glutamatergic input into the putamen and the high excitotoxic susceptibility of neostriatal medium spiny neurons.

Key words

Glutaryl-CoA dehydrogenase - organic acids - acylcarnitines - putamen

References

• 1 Baric I, Wagner L, Buckel W, Hoffmann G F. Sensitivity of free and total glutaric and 3-OH-glutaric acid measurement by stable isotopic dilution assays for the diagnosis of glutaric aciduria type I.  J Inherit Metab Dis. 1999;  22 867-882
• 2 Bennett M J, Marlow N, Pollitt R J, Wales J KH. Glutaric aciduria type I: biochemical investigations and post mortem findings.  Eur J Pediatr. 1986;  145 403-405
• 3 Bjugstad K B, Zawada W M, Goodman S I, Freed C R. IGF-1 and bFGF reduce glutaric acid and 3-hydroxyglutaric acid toxicity in striatal cultures.  J Inherit Metab Dis. 2001;  24 631-647
• 4 Brismar J, Ozand T. CT and NMR of the brain in glutaric acidemia type I: a review of 59 published cases and report of 5 new patients.  Am J Neuroradiol. 1995;  16 675-683
• 5 Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.  Anal Biochem. 1976;  72 248-254
• 6 Calabresi P, Centonze D, Bernardi G. Cellular factors controlling neuronal vulnerability in the brain. A lesson from the striatum.  Neurology. 2000;  55 1249-1255
• 7 Chalmers R A. Organic acids. Lawson AM Mass Spectrometry. Berlin; Walter de Gruyter 1989: 354-403
• 8 Christensen E. A fibroblast glutaryl-CoA dehydrogenase assay using detritiation of ³H ^- labelled glutaryl-CoA: application in the genotyping of the glutaryl-CoA dehydrogenase locus.  Clin Chim Acta. 1993;  220 71-80
• 9 Christensen E, Ribes A, Busquest C, Pineda M, Duran M, Poll-The B T, Greenberg C R, Leffers H, Schwartz M. Compound heterozygosity in the glutaryl-CoA dehydrogenase gene with R227 P mutation in one allele is associated with no or very low free glutarate excretion.  Clin Chim Acta. 1997;  20 383-386
• 10 De Mello C F, Kölker S, Ahlemeyer B, de Souza F R, Fighera M R, Mayatepek E, Krieglstein J, Hoffmann G F, Wajner M. Intrastriatal administration of 3-hydroxyglutaric acid induces convulsions and striatal lesions in rats.  Brain Res. 2001;  916 70-75
• 11 De Sousa C, English N R, Stacey T E, Chalmers R A. Measurement of L-carnitine and acylcarnitines in body fluids and tissues in children and adults.  Clin Chim Acta. 1990;  187 317-328
• 12 Goodman S I, Norenberg M D, Shikes R H, Breslich D J, Moe P G. Glutaric aciduria: biochemical and morphological considerations.  J Pediatr. 1977;  90 746-750
• 13 Goodman S I, Stein D E, Schlesinger S, Christensen E, Schwartz M, Greenberg C R, Elpeleg O N. Glutaryl-CoA dehydrogenase mutations in glutaric acidemia (type I): review and report of thirty novel mutations.  Hum Mutat. 1998;  12 141-144
• 14 Greenberg C R, Duncan A M, Gregory C A, Singal R, Goodman S I. Assignment of human glutaryl-CoA dehydrogenase gene (GCDH) to the short arm of chromosome 19 (19 p13. 2) by in situ hybridization and somatic cell hybrid analysis.  Genomics. 1994;  21 289-290
• 15 Hoffmann G F, Trefz F K, Barth P, Böhles J H, Biggemann B, Bremer H J, Christensen E, Frosch M, Hanefeld F, Hunneman D H, Jacobi H, Kurlemann G, Lawrenz-Wolf B, Rating D, Roe C R, Schutgens R BH, Ullrich K, Weisser J, Wendel U, Lehnert W. Glutaryl-CoA dehydrogenase deficiency: a distinct encephalopathy.  Pediatrics. 1991;  88 1194-1203
• 16 Hoffmann G F, Athanassopoulos S, Burlina A B, Duran M, deKlerck J BC, Lehnert W, Leonard J V, Monavari A A, Müller E, Muntau A C, Naughten E R, Plecko-Starting B, Superti-Furga A, Zschocke J, Christensen E. Clinical course, early diagnosis, treatment and prevention of disease in glutaryl-CoA dehydrogenase deficiency.  Neuropediatrics. 1996;  27 115-123
• 17 Hoffmann G F, Zschocke J. Glutaric aciduria type I: from clinical, biochemical and molecular diversity to successful therapy.  J Inherit Metab Dis. 1999;  22 381-391
• 18 Hollmann M, Heinemann S. Cloned glutamate receptors.  Annu Rev Neurosci. 1994;  17 31-108
• 19 Holmes G L, Ben-Ari Y. The neurobiology and consequences of epilepsy in the developing brain.  Pediatr Res. 2001;  49 320-325
• 20 Johnston M V, Hoon A H. Possible mechanisms in infants for selective basal ganglia damage from asphyxia, kernicterus or mitochondrial encephalopathies.  J Child Neurol. 2000;  15 588-591
• 21 Koeller D M, DiGiulio K A, Angeloni S V, Dowler L L, Frerman F E, White R A, Goodman S I. Cloning, structure, and chromosome localization of the mouse glutaryl-CoA dehydrogenase gene.  Genomics. 1995;  28 508-512
• 22 Kölker S, Ahlemeyer B, Krieglstein J, Hoffmann G F. Maturation-dependent neurotoxicity of 3-hydroxyglutaric and glutaric acids in vitro: a new pathophysiologic approach to glutaryl-CoA dehydrogenase deficiency.  Pediatr Res. 2000;  47 495-503
• 23 Kölker S, Ahlemeyer B, Krieglstein J, Hoffmann G F. Contribution of reactive oxigen species to 3-hydroxyglutarate neurotoxicity in primary neuronal cultures from chick embryo telemcephalons.  Pediatr Res. 2001;  50 76-82
• 24 Kölker S, Ahlemeyer B, Hühne R, Krieglstein J, Hoffmann G F. Potentiation of 3-hydroxyglutarate neurotoxicity following induction of astrocytic iNOS in neonatal rat hippocampal cultures.  Eur J Neurosci. 2001;  13 2115-2122
• 25 Kölker S, Köhr G, Ahlemeyer B, Okun J G, Pawlak V, Hörster F, Mayatepek E, Krieglstein J, Hoffmann G F. Ca²⁺ and Na⁺ dependence of 3-hydroxyglutarate-induced excitotoxicity in primary neuronal cultures from chick embryo telencephalons.  Pediatr Res. 2002;  52 199-206
• 26 Kyllerman M, Steen G. Glutaric aciduria. A “common” metabolic disorder?.  Arch Fr Pediatr. 1980;  37 279
• 27 Landwehrmeyer G B, Standaert D G, Testa C M, Penney J B, Young A B. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum.  Neuroscience. 1995;  15 5297-5307
• 28 Leibel R L, Shih V E, Goodman S I, Bauman M L, McCabe E RB, Zwerdling R G, Bergman I, Costello C. Glutaric acidemia: a metabolic disorder causing progressive choreoathetosis.  Neurology. 1980;  30 1163-1168
• 29 McDermott A B, Mayer M L, Westbrook G L, Smith S L, Barker J L. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurons.  Nature. 1986;  321 519-522
• 30 McDonald J W, Johnston M V. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development.  Brain Res Reviews. 1990;  15 41-70
• 31 Monyer H, Burnashev N, Laurie D J. Development and regional expression in the rat brain and functional properties of four NMDA receptors.  Neuron. 1993;  12 529-540
• 32 Okun J G, Hörster F, Farkas L M, Feyh P, Hinz A, Sauer S, Hoffmann G F, Unsicker K, Mayatepek E, Kölker S. Neurodegeneration in methylmalonic acidurias involves inhibition of complex II and the tricarboxylic acid cycle, and synergistically acting excitotoxicity.  J Biol Chem. 2002;  277 14674-14680
• 33 Schor D SM, Verhoeven N, Struys E, ten Brink H, Jakobs C. Quantification of 3-hydroxyglutaric acid in urine, plasma, cerebrospinal fluid and amniotic fluid by stable-isotope dilution negative chemical ionization gas chromatography-mass spectrometry.  J Chromatogr B Analyt Technol Biomed Life Sci. 2002;  780 199-204
• 34 Ullrich K, Flott-Rahmel B, Schluff P, Musshoff U, Das A, Lücke T, Steinfeld R, Christensen E, Jakobs C, Ludolph A, Neu A, Roper R. Glutaric aciduria type I: pathomechanism of neurodegeneration.  J Inherit Metab Dis. 1999;  22 392-403
• 35 Woontner M, Crnic L S, Koeller D M. Analysis of the expression of murine glutaryl-CoA dehydrogenase: in vitro and in vivo studies.  Mol Genet Metab. 2000;  69 116-122
• 36 Zschocke J, Quak E, Guldberg P, Hoffmann G F. Mutation analysis in glutaric aciduria type I.  J Med Genet. 2000;  37 177-181